These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2994 related articles for article (PubMed ID: 33734299)

  • 1. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.
    ; Sadeghipour P; Talasaz AH; Rashidi F; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Jamalkhani S; Khalili H; Yadollahzadeh M; Riahi T; Rezaeifar P; Tahamtan O; Matin S; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Bakhshandeh H; Amin A; Rafiee F; Baghizadeh E; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Dobesh PP; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Bikdeli B
    JAMA; 2021 Apr; 325(16):1620-1630. PubMed ID: 33734299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial.
    Bikdeli B; Talasaz AH; Rashidi F; Bakhshandeh H; Rafiee F; Rezaeifar P; Baghizadeh E; Matin S; Jamalkhani S; Tahamtan O; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Khalili H; Yadollahzadeh M; Riahi T; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Amin A; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Dobesh PP; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Sadeghipour P
    Thromb Haemost; 2022 Jan; 122(1):131-141. PubMed ID: 33865239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies.
    Bikdeli B; Talasaz AH; Rashidi F; Sharif-Kashani B; Farrokhpour M; Bakhshandeh H; Sezavar H; Dabbagh A; Beigmohammadi MT; Payandemehr P; Yadollahzadeh M; Riahi T; Khalili H; Jamalkhani S; Rezaeifar P; Abedini A; Lookzadeh S; Shahmirzaei S; Tahamtan O; Matin S; Amin A; Parhizgar SE; Jimenez D; Gupta A; Madhavan MV; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Mohebbi B; Piazza G; Kirtane AJ; Lip GYH; Krumholz HM; Goldhaber SZ; Sadeghipour P
    Thromb Res; 2020 Dec; 196():382-394. PubMed ID: 32992075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial.
    INSPIRATION-S Investigators
    BMJ; 2022 Jan; 376():e068407. PubMed ID: 34996756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
    Spyropoulos AC; Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Mignatti A; Gianos E; Cohen M; Sharifova G; Lund JM; Tafur A; Lewis PA; Cohoon KP; Rahman H; Sison CP; Lesser ML; Ochani K; Agrawal N; Hsia J; Anderson VE; Bonaca M; Halperin JL; Weitz JI;
    JAMA Intern Med; 2021 Dec; 181(12):1612-1620. PubMed ID: 34617959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial.
    Lopes RD; de Barros E Silva PGM; Furtado RHM; Macedo AVS; Ramacciotti E; Damini LP; Bronhara B; Cavalcanti AB; Rosa RG; Azevedo LCP; Veiga VC; Machado FR; Ritt LE; Martins PA; Alexander JH; Avezum A; Berwanger O;
    Am Heart J; 2021 Aug; 238():1-11. PubMed ID: 33891907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
    Weitz JI; Bauersachs R; Becker B; Berkowitz SD; Freitas MCS; Lassen MR; Metzig C; Raskob GE
    JAMA; 2020 Jan; 323(2):130-139. PubMed ID: 31935028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT.
    Bohula EA; Berg DD; Lopes MS; Connors JM; Babar I; Barnett CF; Chaudhry SP; Chopra A; Ginete W; Ieong MH; Katz JN; Kim EY; Kuder JF; Mazza E; McLean D; Mosier JM; Moskowitz A; Murphy SA; O'Donoghue ML; Park JG; Prasad R; Ruff CT; Shahrour MN; Sinha SS; Wiviott SD; Van Diepen S; Zainea M; Baird-Zars V; Sabatine MS; Morrow DA;
    Circulation; 2022 Nov; 146(18):1344-1356. PubMed ID: 36036760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
    Krueger K; Schmutz A; Zieger B; Kalbhenn J
    Artif Organs; 2017 Feb; 41(2):186-192. PubMed ID: 27256966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial.
    Berger JS; Kornblith LZ; Gong MN; Reynolds HR; Cushman M; Cheng Y; McVerry BJ; Kim KS; Lopes RD; Atassi B; Berry S; Bochicchio G; de Oliveira Antunes M; Farkouh ME; Greenstein Y; Hade EM; Hudock K; Hyzy R; Khatri P; Kindzelski A; Kirwan BA; Baumann Kreuziger L; Lawler PR; Leifer E; Lopez-Sendon Moreno J; Lopez-Sendon J; Luther JF; Nigro Maia L; Quigley J; Sherwin R; Wahid L; Wilson J; Hochman JS; Neal MD;
    JAMA; 2022 Jan; 327(3):227-236. PubMed ID: 35040887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and Therapeutic Anticoagulation in Patients With Hypoxemic COVID-19 Pneumonia: The ANTICOVID Randomized Clinical Trial.
    Labbé V; Contou D; Heming N; Megarbane B; Razazi K; Boissier F; Ait-Oufella H; Turpin M; Carreira S; Robert A; Monchi M; Souweine B; Preau S; Doyen D; Vivier E; Zucman N; Dres M; Fejjal M; Noel-Savina E; Bachir M; Jaffal K; Timsit JF; Picos SA; Mariotte E; Martis N; Juguet W; Melica G; Rondeau P; Audureau E; Mekontso Dessap A;
    JAMA Intern Med; 2023 Jun; 183(6):520-531. PubMed ID: 36946232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catheter-Directed Thrombolysis vs Anticoagulation in Patients With Acute Intermediate-High-risk Pulmonary Embolism: The CANARY Randomized Clinical Trial.
    Sadeghipour P; Jenab Y; Moosavi J; Hosseini K; Mohebbi B; Hosseinsabet A; Chatterjee S; Pouraliakbar H; Shirani S; Shishehbor MH; Alizadehasl A; Farrashi M; Rezvani MA; Rafiee F; Jalali A; Rashedi S; Shafe O; Giri J; Monreal M; Jimenez D; Lang I; Maleki M; Goldhaber SZ; Krumholz HM; Piazza G; Bikdeli B
    JAMA Cardiol; 2022 Dec; 7(12):1189-1197. PubMed ID: 36260302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep vein thrombosis in hospitalized patients with coronavirus disease 2019.
    Chang H; Rockman CB; Jacobowitz GR; Speranza G; Johnson WS; Horowitz JM; Garg K; Maldonado TS; Sadek M; Barfield ME
    J Vasc Surg Venous Lymphat Disord; 2021 May; 9(3):597-604. PubMed ID: 33039545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial.
    Perepu US; Chambers I; Wahab A; Ten Eyck P; Wu C; Dayal S; Sutamtewagul G; Bailey SR; Rosenstein LJ; Lentz SR
    J Thromb Haemost; 2021 Sep; 19(9):2225-2234. PubMed ID: 34236768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19.
    Cosmi B; Giannella M; Fornaro G; Cristini F; Patacca A; Castagna A; Mazzaferri F; Testa S; Pan A; Lupi M; Brambilla P; Montineri A; Frattima S; Bignami EG; Salvetti M; De Stefano G; Grandone E; Di Perri G; Rozzini R; Stella A; Romagnoli A; Drago F; Viale P
    BMC Infect Dis; 2023 Oct; 23(1):718. PubMed ID: 37875792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia.
    Tacquard C; Mansour A; Godon A; Godet J; Poissy J; Garrigue D; Kipnis E; Rym Hamada S; Mertes PM; Steib A; Ulliel-Roche M; Bouhemad B; Nguyen M; Reizine F; Gouin-Thibault I; Besse MC; Collercandy N; Mankikian S; Levy JH; Gruel Y; Albaladejo P; Susen S; Godier A;
    Chest; 2021 Jun; 159(6):2417-2427. PubMed ID: 33465342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial.
    Connors JM; Brooks MM; Sciurba FC; Krishnan JA; Bledsoe JR; Kindzelski A; Baucom AL; Kirwan BA; Eng H; Martin D; Zaharris E; Everett B; Castro L; Shapiro NL; Lin JY; Hou PC; Pepine CJ; Handberg E; Haight DO; Wilson JW; Majercik S; Fu Z; Zhong Y; Venugopal V; Beach S; Wisniewski S; Ridker PM;
    JAMA; 2021 Nov; 326(17):1703-1712. PubMed ID: 34633405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of deep venous thrombosis in COVID-19 critically ill patients treated with intermediate-dose of heparin for thromboprophylaxis: The COVIDOP-DVT observational study.
    Maurizot A; Chabay S; Roger G; Tapiero S; Georges JL; Flaujac C; Paul M; Roche A; Bruneel F; Ferré A
    Vascular; 2024 Oct; 32(5):1099-1106. PubMed ID: 37009990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial.
    Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Sharifova G; Cohen M; Lund JM; Mignatti A; Gianos E; Tafur A; Lewis PA; Cohoon K; Kittelson JM; Lesser ML; Sison CP; Rahman H; Ochani K; Hiatt WR; Dale RA; Anderson VE; Bonaca M; Halperin JL; Weitz JI; Spyropoulos AC
    Thromb Haemost; 2021 Dec; 121(12):1684-1695. PubMed ID: 33823560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes.
    INSPIRATION INVESTIGATORS
    Eur J Intern Med; 2022 Sep; 103():76-83. PubMed ID: 35879217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 150.